Cardiac Arrhythmias

Drawing of heart diagram with parts of the heart labeled a-i
World-Class Cardiac Arrhythmia Management 

Confronting the burden of cardiac arrhythmias

The global burden of cardiac arrhythmias is staggering. Patients with atrial tachycardias (ATs) and atrial fibrillation (AF) face an increased risk for stroke, dementia, heart failure and death,1 and the number of patients with AF is expected to double in the next 40 years.2 Ventricular tachycardia (VT) and ventricular fibrillation (VF) are even more serious. Sustained VT is fatal. Analysts estimate that annually almost 4 million people experience sudden cardiac death worldwide, with about half of those deaths attributed to VT,3 including approximately 300,000 in the United States.4

Arrhythmia management is multifaceted, requiring creative solutions that span the patient care continuum–from insight to therapy. Our arrhythmia management portfolios give you the options you need to precisely diagnose, treat and manage arrhythmias with versatility and efficacy. When it comes to understanding and managing cardiac arrhythmias, we are your partner for life.

Related Portfolios

Learn about our other advanced portfolio solutions to help manage your patients’ cardiac arrhythmias.

Remote Monitoring Portfolio

Our remote monitoring portfolio, with™ Patient Care Network and Merlin@home™ wireless transmitter can help you optimize workflow, support informed clinical decisions and deliver efficient, comprehensive care.

Arrhythmia Management

Our arrhythmia management portfolio helps you monitor and treat patients with a range of cardiac arrhythmias, and includes our ICDs, pacemakers and leads. Our products include innovative patient-safety features, including parylene coating, customizable programming and lead insulations.

Automated. Flexible. Precise.

Part of our advanced ablation and mapping portfolio as well as our integrated lab portfolio, the EnSite Precision™ cardiac mapping system is one of our next-generation solutions designed to provide critical mapping information for diagnosing a wide range of arrhythmias and to integrate with current and future technologies.

The EnSite Precision system meets the expectations of today’s electrophysiology; it’s precise, it’s reliable, it’s accurate and it’s fast.
—Dr. Gerhard Hindricks*

Watch Dr. Gerhard Hindricks and Dr. Philipp Sommer of the University of Leipzig Heart Center discuss the EnSite Precision cardiac mapping system, then learn more about our advanced ablation and mapping portfolio and our integrated lab portfolio.

Innovative Technology to Improve Quality of Life and Reduce Mortality Rates

At Abbott, we remain committed to developing effective, innovative technologies that help you treat and monitor AT and AF as well as VT and VF. Like you, we want to see permanent relief for patients all over the world who suffer from cardiac arrhythmias. In 2005, Abbott dedicated an entire business unit to creating curative therapies for the treatment of AF. Since that time, we have consistently invested 12 to 13 percent of our total revenue toward the research and development of cutting-edge technologies and clinical advancements across all therapy areas. 

We invest resources in transforming health care, and our investments have brought these advances: 

  • Contact force ablation to monitor the force applied at each ablation location and potentially avoid risks related to the application of too little or too much force8,9,10
  • Enabled navigation of devices on prerecorded X-ray images for the reduction of radiation dose11
Infographic states 46.1 million people worldwide have AF (0.5% of the world

Remote Monitoring Potential Benefits

Infographic shows ICD/CRT-D patients' potential for 34% reduction in all-cause mortality over 3 yearsInfographic shows a potential for 50% lower risk of all-cause mortality in ICD patientInfographic states pacemaker patients have the potential for 27% reduction in all-cause mortality over 3 years

Transforming the Treatment of Cardiac Arrhythmias

Our vision is to transform the treatment of cardiac arrhythmias and other expensive epidemic diseases by creating innovative, cost-effective technologies that are effective for healthcare professionals and patients alike. We back our innovation with clinical leadership by building a body of evidence that proves the safety, efficacy and cost-effectiveness of our transformative therapies.

See clinical studies

Cardiovascular diseases (CVDs) are the No. 1 cause of death globally, accounting for 30% of all deaths worldwide.14

Designed in Partnership With Physicians

Part of our advanced ablation and mapping portfolio and designed in partnership with physicians, the FlexAbility™ Ablation Catheter has a novel flexible tip and an advanced handle-shaft combination, demonstrating safety and effectiveness in both clinical and pre-clinical studies.

See clinical results.

When you look at the time of the disappearance of the electrogram, it… went faster than what I’m used to with other catheters.
—Dr. Andrea Natale

Watch the FlexAbility™ ablation catheter at work in a real case, then learn more about our advanced ablation and mapping portfolio.

Advancing Cost-Effective Therapies

Cardiac arrhythmias impact millions of adults worldwide, and experts expect that number to increase dramatically.2 In order to combat the growing prevalence of and rising costs associated with cardiac arrhythmias, we focus on developing technologies that will improve patient quality of care and decrease the substantial economic burden that comes with hospitalization and treatment. 

In order to address the rising costs of cardiac arrhythmias, we have designed the products in our cardiac arrhythmia management portfolios to:

  • Reduce ablation procedure time with the TactiCath™ Quartz contact force ablation catheter16
  • Reduce duration of fluoroscopy time** with MediGuide™ Technology11
  • Reduce the number of hospital admissions as a result of remote monitoring17
  • Reduce the frequency of patient visits and in-person follow-ups as a result of remote monitoring13
  • Reduce patient length of stay per hospitalization as a result of remote monitoring13
  • Improve clinical and lab workflow and efficiency with products in our integrated lab portfolio18
Infographic states by 2030 medical costs for CVD will triple from $263 billion to $818 billion


*Reduction in duration of fluoroscopy time is defined as reduction in duration of live X-ray.
1. Estes, N. A., Sacco, R. L., Al-Khatib, S. M., Ellinor, P. T., Bezanson, J., Alonso, A., … Benjamin, E. J. (2011). American Heart Association atrial fibrillation research summit: A conference report from the American Heart Association. Circulation, 124, 363-372.
2. Sullivan, E., Braithwaite, S., Dietz, K., & Hickey, C. (2010). Health services utilization and medical costs among Medicare atrial fibrillation patients. Avalere Health, 4, 2,7,9.
3. John, R. M., Tedrow, U. B., Koplan, B. A., Albert, C. M., Epstein, L. M., Sweeney, M. O., … Stevenson, W. G. (2012). Ventricular arrhythmias and sudden cardiac death. The Lancet, 380(9852), 1520-1529.
4. Stecker, E. C., Reinier, K., Marijon, E., Narayanan, K. Teodorescu, C. Uy-Evanado. A., … Chugh, S. S. (2014). Public health burden of sudden cardiac arrest in the United States. Circulation: Arrhythmia and Electrophysiology, 7(2), 212-217.
5. Mittal, S., Piccini, J., Fischer, A., Snell, J., Dalal, N., & Varma, N. (2014, May). Remote monitoring of ICD patients is associated with reduced mortality irrespective of device type. Presented at the meeting of the Heart Rhythm Society, San Francisco, CA. This was a retrospective data review and had limitations.
6. Choudhuri, I., Desai, D., Walburg, J., August, P., Keller, S. I., & Suri, R. (2012). Feasibility of early discharge after implantable cardioverter-defibrillator procedures. Journal of Cardiovascular Electrophysiology, 23(10), 1123-1129. 10.1111/j.1540-8167.2012.02367.x
7. Sutton, B., Zigler, J., Gopinathannair, R., Deam, G., & Graver, R. (2013, May). Improved health outcomes and cost-savings with remote monitoring of cardiac implantable electronic devices. Presented at the meeting of the Heart Rhythm Society, Denver, CO. Retrospective claims analysis of Medicare 5% sample Limited Data Set Standard Analytical Files claims and enrollment data across all manufacturers.
8. Kuck K. H., Reddy, V.Y., Schmidt, B., Natale, A., Neuzil, P. Saoudi, N., … Shah, D. C. (2012). A novel radiofrequency ablation catheter using contact force sensing: Toccata study. Heart Rhythm, 9(1), 18-23. 10.1016/j.hrthm.2011.08.021
9. Reddy, V., Shah, D., Kautzner, J., Schmidt, B., Saoudi, N., Herrera, C., … Kuck, K. H. (2012). The relationship between contact force and clinical outcome during radiofrequency catheter ablation of atrial fibrillation in the TOCCATA study. Heart Rhythm, 9(11), 1789-1795.
10. Neuzil, P., Reddy, V., Kautzner, J., Petru, J. Wichterle, D., Shah, D., … Kuck, K. H. (2013). Electrical reconnection after pulmonary vein isolation is contingent on contact force during initial treatment: Results from the EFFICAS I Study. Circulation: Arrhythmia and Electrophysiology, 6(2), 327-333.
11. Rolf. S., Sommer, P., Gaspar, T., John, S., Hindricks, G., & Piorkowski, C. (2012). Ablation of atrial fibrillation using novel 4-dimensional catheter tracking within autoregistered left atrial angiograms. Circulation, Arrhythmia and Electrophysiology, 5, 684-690.
12. Richter, S., Doering, M., Gaspar, T., John, S., Rolf, S., Sommer, P., Hindricks, G., & Piorkowski, C. (2013). Cardiac resynchronization therapy device implantation using a new sensor-based navigation system: Results from the first human use study. Circulation: Arrhythmia and Electrophysiology, 6(5), 917-923.
13. Varma, N., Epstein, A. E., Irimpen, A., Schweikert, R., Love, C., & TRUST Investigators. Efficacy and safety of automatic remote monitoring for implantable cardioverter defibrillator follow-up: The Lumos-T Safely Reduces Routine Office Device Follow-Up (TRUST) trial. Circulation, 122, 325-332.
14. Chugh, S. S., Havmoeller, R., Narayanan, K., Singh, D., Rienstra, N., Benjamin, E., … Murray, C. (2014). Worldwide epidemiology of atrial fibrillation: A global burden of disease 2010 study. Circulation, 129(8), 837-847.
15. World Health Organization. Cardiovascular Diseases (CVDs). Retrieved from
16. Schreieck, J., Weig, H. J., Kerst, G., et. al. (2012). Force controlled RF ablation increases effectivity for AF ablation using PV isolation. Clinical Research in Cardiology, 101(Suppl. 1), 660.
17. Crossley, G. H., Boyle, A., Vitense, H., Chang, Y., Mead, R. H., & CONNECT Investigators. (2011). The CONNECT (Clinical Evaluation of Remote Notification to Re-duce Time to Clinical Decision) trial: The value of wireless remote monitoring with automatic clinician alerts. Journal of the American College of Cardiology, 57(10), 1181-1189.
18. Winkle, R. A., Mead, R. H., Engel, G., Kong, M. H., & Patrawala, R. A. (2013). Physician-controlled costs: The choice of equipment used for atrial fibrillation ablation. Journal of Interventional Cardiac Electrophysiology, 36(2), 157-165. Figure 1.

Orange 24 surrounded by headset, represents "Place an order"

Contact Customer Service

Our customer service experts can help with your product orders or questions.